Nafithromycin
A macrolide antibiotic
| Nafithromycin | |
|---|---|
| [[File: Error creating thumbnail: Chemical structure of Nafithromycin | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Nafithromycin is a novel macrolide antibiotic that is being developed for the treatment of bacterial infections. It belongs to the class of antibiotics known as ketolides, which are derived from macrolides and are designed to overcome certain types of bacterial resistance.
Mechanism of Action[edit | edit source]
Nafithromycin works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby interfering with the translocation step in protein synthesis. This action prevents the growth and replication of bacteria, making it effective against a variety of Gram-positive bacteria.
Clinical Uses[edit | edit source]
Nafithromycin is primarily being investigated for its use in treating community-acquired pneumonia and other respiratory tract infections. Its efficacy against macrolide-resistant strains of bacteria makes it a promising candidate for treating infections that are difficult to manage with existing antibiotics.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Nafithromycin includes its absorption, distribution, metabolism, and excretion. It is designed to have a favorable bioavailability when administered orally, and it is metabolized in the liver. The elimination half-life allows for convenient dosing schedules, which can improve patient compliance.
Development and Research[edit | edit source]
Nafithromycin is currently undergoing clinical trials to evaluate its safety and efficacy. Research is focused on its potential to treat infections caused by resistant strains of bacteria, which is a growing concern in the field of infectious diseases.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
